These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 17638398)

  • 21. Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe.
    Mashingaidze-Mano R; Bwakura-Dangarembizi MF; Maponga CC; Morse GD; Monera-Penduka TG; Mtisi TJ; Mudzviti T; Mujuru HA
    PLoS One; 2020; 15(7):e0235759. PubMed ID: 32634168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
    J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
    Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
    AIDS; 2007 Jul; 21(11):1431-9. PubMed ID: 17589189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight.
    Chaisiri K; Bowonwatanuwong C; Kasettratat N; Kiertiburanakul S
    Curr HIV Res; 2010 Oct; 8(7):504-9. PubMed ID: 21073439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians.
    Agbaji OO; Agaba PA; Idoko JA; Taiwo B; Murphy R; Kanki P; Ekong E
    West Afr J Med; 2011; 30(3):164-8. PubMed ID: 22120479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
    Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
    PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
    De Beaudrap P; Diallo MB; Landman R; Guèye NF; Ndiaye I; Diouf A; Kane CT; Etard JF; Girard PM; Sow PS; Delaporte E;
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1221-7. PubMed ID: 20854202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
    Pontrelli G; Cotugno N; Amodio D; Zangari P; Tchidjou HK; Baldassari S; Palma P; Bernardi S
    BMC Infect Dis; 2012 Jan; 12():18. PubMed ID: 22269183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
    Maggi P; Montinaro V; Bellacosa C; Pietanza S; Volpe A; Graziano G; Strippoli GF; Angarano G
    AIDS Patient Care STDS; 2012 Jan; 26(1):5-11. PubMed ID: 22136504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Assessment of renal abnormalities in 107 HIV patients treated with tenofovir].
    Lochet P; Peyrière H; Le Moing V; Blayac JP; Hansel S; Reynes J
    Therapie; 2005; 60(2):175-81. PubMed ID: 15969320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project.
    Madeddu G; Bonfanti P; De Socio GV; Carradori S; Grosso C; Marconi P; Penco G; Rosella E; Miccolis S; Melzi S; Mura MS; Landonio S; Ricci E; Quirino T;
    Biomed Pharmacother; 2008 Jan; 62(1):6-11. PubMed ID: 17574807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.
    Gatanaga H; Tachikawa N; Kikuchi Y; Teruya K; Genka I; Honda M; Tanuma J; Yazaki H; Ueda A; Kimura S; Oka S
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):744-8. PubMed ID: 16910829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy.
    Biagi M; Badowski M; Chiampas T; Young J; Vaughn P; Shicker L; Patel M
    Int J STD AIDS; 2016 Aug; 27(9):808-11. PubMed ID: 26378193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians.
    Lao CK; Gruta C; John MD; Cocohoba J
    J Natl Med Assoc; 2011 Jun; 103(6):518-22. PubMed ID: 21830636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrent bone fractures due to tenofovir-induced renal phosphate wasting.
    Koenig KF; Kalbermatter S; Menter T; Graber P; Kiss D
    Scand J Infect Dis; 2014 Mar; 46(3):221-4. PubMed ID: 24147545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal function with use of a tenofovir-containing initial antiretroviral regimen.
    Gallant JE; Moore RD
    AIDS; 2009 Sep; 23(15):1971-5. PubMed ID: 19696652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
    Prescrire Int; 2014 May; 23(149):124-5. PubMed ID: 24926511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is phosphatemia the best tool to monitor renal tenofovir toxicity?
    Essig M; Duval X; Kaied FA; Iordache L; Gervais A; Longuet P; Blanchet F; Peytavin G; Leport C
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):256-8. PubMed ID: 17895770
    [No Abstract]   [Full Text] [Related]  

  • 40. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
    Cooper RD; Wiebe N; Smith N; Keiser P; Naicker S; Tonelli M
    Clin Infect Dis; 2010 Sep; 51(5):496-505. PubMed ID: 20673002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.